Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine/naloxone - Orexo

Next Previous
Drug Profile

Buprenorphine/naloxone - Orexo

Alternative Names: Naloxone/buprenorphine - Orexo; OX-219; PKX-219; Zubsolv

Latest Information Update: 27 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmaKodex
  • Developer Orexo
  • Class Antidotes; Benzofurans; Cyclopropanes; Drug withdrawal therapies; Isoquinolines; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Opioid-related disorders

Most Recent Events

  • 24 Jul 2023 Sun Pharmaceutical Industries appealed the patent litigation decision issued by the US District Court for the District of New Jersey relating to Orexo's patents protecting ZUBSOLV® in the US
  • 01 Jul 2023 Orexo wins patent litigation against Sun Pharmaceuticals regarding buprenorphine/naloxone (ZUBSOLV®)submission in USA
  • 30 Dec 2020 Orexohas patent protection for buprenorphine/naloxone in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top